Text Size

Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide (REPAMET 2)

This study has been completed.
Sponsor:
Information provided by:
Novo Nordisk
ClinicalTrials.gov Identifier:
NCT00745433
First received: September 1, 2008
Last updated: June 5, 2012
Last verified: November 2011
History of Changes
  Purpose

This study is conducted in Europe. The aim of this observational study is to investigate the efficacy (e.g. glycemic control) and safety (e.g. hypoglycemic episodes) when adding repaglinide to a monotherapy of metformin in type 2 diabetic patients under normal clinical practice


Condition Intervention
Diabetes
Diabetes Mellitus, Type 2
 Drug: repaglinide
Drug: metformin

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: REPAMET 2: Observational Study of the Switch From Metformin Monotherapy to Bitherapy With Metformin and Repaglinide

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Novo Nordisk:

Primary Outcome Measures:
  • HbA1c [ Time Frame: After 12-20 weeks. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • PPG [ Time Frame: After 12-20 weeks. ] [ Designated as safety issue: No ]
  • Number of hypoglycemic events [ Time Frame: After 12-20 weeks. ] [ Designated as safety issue: Yes ]
  • Variability in FPG (Fasting Plasma Glucose) [ Time Frame: After 12-20 weeks. ] [ Designated as safety issue: No ]

Enrollment: 906
Study Start Date: January 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
A
Repaglinide add-on to metformin.
 Drug: repaglinide
Start dose and frequency at the discretion of the physician following clinical practice
Other Name: NovoNorm®
Drug: metformin
Start dose and frequency at the discretion of the physician following clinical practice

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Any subject with type 2 diabetes treated with metformin

Criteria

Inclusion Criteria:

  • Type 2 diabetes
  • Metformin monotreatment
  • HbA1c greater than 7%
  • Treatment according to SPC
  • Informed consent obtained

Exclusion Criteria:

  • Any contraindication to the use of repaglinide (according to the SPC)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00745433

Locations
Belgium
Brussels, Belgium, 1070
Sponsors and Collaborators
Novo Nordisk
Investigators
Study Director: Dirk D'Hooge sa Novo Nordisk Pharma
  More Information

Additional Information:
Clinical Trials at Novo Nordisk  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Public Access to Clinical Trials, Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT00745433     History of Changes
Other Study ID Numbers: AGEE-3558
Study First Received: September 1, 2008
Last Updated: June 5, 2012
Health Authority: Belgium: Federal Agency for Medicines and Health Products

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
 Repaglinide
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 19, 2013